OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	96
Future options for long-acting HIV treatment and prevention	67
The sounds of silencing: dynamic epigenetic control of HIV latency	44
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	33
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	29
Harnessing natural killer cells to target HIV-1 persistence	28
Editorial introductions	26
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	25
Editorial introduction	25
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	25
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	21
Editorial introduction	20
Challenges towards an AIDS-free generation in Africa and Asia	20
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	20
Persistent elite controllers as the key model to identify permanent HIV remission	19
Editorial introduction	18
New latency-promoting agents for a block-and-lock functional cure strategy	18
Balancing polypharmacy and comorbidity management: cardiovascular health	17
Defining multimorbidity in people with HIV – what matters most?	17
The origins of new SARS-COV-2 variants in immuncompromised individuals	17
Loneliness and social isolation in people with HIV	17
Immunological effector mechanisms in HIV-1 elite controllers	17
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	16
Role of follicular homing natural killer cells in HIV infection	16
Viral and immune predictors of HIV posttreatment control	16

Editorial introduction	14
Impact of coronavirus disease 2019 on co-morbidities in HIV	14
Renal adverse drug reactions	12
Mpox and the impact on people with HIV	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
The multifaceted nature of HIV tissue reservoirs	11
Obesity among women with HIV	11
Aging of adult lifetime survivors with perinatal HIV	11
Beyond criminalization: reconsidering HIV criminalization in an era of reform	10
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	10
The severity of COVID-19 across the spectrum of HIV	10
Host factors predisposing to kidney disease in people with HIV	10
Broadly neutralizing antibodies for HIV treatment and cure approaches	10
Metabolic dysfunction-associated steatotic liver disease in people with HIV	10
Editorial: New drugs for HIV: quo vadis?	10
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	10
Gender and sex considerations in HIV and bone health	10
HIV and cardiovascular disease: the role of inflammation	10
Strategies to target the central nervous system HIV reservoir	9
Causes and outcomes of hepatic fibrosis in persons living with HIV	8
Editorial introduction	8
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	8
Persistent HIV-1 transcription during ART: time to reassess its significance?	8
Innovative models of care supporting people aging with HIV	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
HIV drug resistance in various body compartments	7
Editorial: Is it time to implement injectable antiretroviral treatments globally?	7
Editorial introduction	7
Editorial introductions	7
Editorial introductions	7
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
HIV-1 subtypes and latent reservoirs	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	6
The pathogenesis of obesity in people living with HIV	6
Whole person HIV services: a social science approach	6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	6
Towards an HIV cure: one cell at a time	5
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	5
Towards a molecular profile of antiretroviral therapy-free HIV remission	5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	5
Scaling up preexposure prophylaxis to maximize HIV prevention impact	5
Editorial introductions	5
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua	5
Role of islatravir in HIV treatment and prevention: an update	5
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	4
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	4
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	4
Cardiovascular disease risk in women living with HIV	4

Editorial introductions	4
Humanized mice for studying HIV latency and potentially its eradication	4
Care of people aging with HIV in resource limited settings	4
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	4
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	4
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	4
Editorial introductions	4
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	4
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
Management of pain and other palliative needs in older people with HIV	3
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	3
Considerations for successful therapeutic immunization in HIV cure	3
Delivery platforms for broadly neutralizing antibodies	3
Post-intervention control in HIV immunotherapy trials	3
Editorial introduction	3
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	3
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	3
Monocytes across life span in HIV infection: lights and shadows	3
Editorial introduction	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
Pediatric immunotherapy and HIV control	3
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	3
Zika virus: an overview update	3
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	2
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	2
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	2
Stepping stones to cure in children with HIV	2
Hepatotoxicity of contemporary antiretroviral drugs	2
Pulmonary comorbidities in people with HIV− the microbiome connection	2
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	2
The future of long-acting agents for preexposure prophylaxis	2
Editorial introductions	2
Elite controllers microbiome: unraveling the mystery of association and causation	2
Utilizing immunotherapy towards achieving a functional cure for HIV-1	2
Editorial introductions	2
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	2
HIV T-cell immunogen design and delivery	2
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	2
Understanding residual risk of cardiovascular disease in people with HIV	2
Promises and challenges: cabotegravir for preexposure prophylaxis	2
HIV and obesity: updates in management strategies	2
Editorial introductions	2
The vaginal microbiome and HIV transmission dynamics	2